CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 227 enrolled
Drug / intervention
Certolizumab Pegol +1 morebiological
Likely dose
Certolizumab Pegol 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02326272
NCT02326272Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

UCB Biopharma S.P.R.L.·interventional·Posted Dec 29, 2014·Updated Oct 3, 2019

In Brief

A Phase 3 clinical trial evaluating Certolizumab Pegol and Placebo for Psoriasis and Plaque Psoriasis. Completed, enrolled 227 participants across 23 sites in 4 countries.

Detailed Summary

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Plaque Psoriasis
CountriesAustria, Canada, Poland, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 29, 2014
Enrollment StartDec 15, 2014
Primary CompletionJan 5, 2016
Study CompletionSep 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.5 years ago

Interventions

Certolizumab Pegolbiological

* Active Substance: Certolizumab Pegol * Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 200 mg/mL * Route of Administration: Subcutaneous use

Placeboother

* Active Substance: Placebo * Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 0.9 % saline * Route of Administration: Subcutaneous use